Seek Early Experience: Don’t wait until you feel like an expert to look for internships or entry-level roles. Getting some ...

That said, Recursion doesn't have a single therapy on the market yet. Over the past four years, the company has made little notable clinical progress. Like most clinical-stage biotechs, Recursion ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...

JavaScript’s low bar to entry has resulted in one of the richest programming language ecosystems in the world. This month’s report celebrates the bounty, while also highlighting a recent example of ...

Earlier this week, the Npm package manager suffered what may be its worst security incident to date. Unknown cybercriminals ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was triggered by the initiation of additional preclinical ...